Occult hepatitis B infection and transfusion-transmission risk
Copyright © 2017 Elsevier Masson SAS. All rights reserved..
Advances in serology and viral nucleic acid testing (NAT) over the last decades significantly reduced the risk of transfusion-transmitted hepatitis B virus (HBV). The combination of HBsAg testing and NAT efficiently prevents the majority of HBV transmission. However, a specific residual risk remains associated with extremely low viral DNA levels in blood donors with occult HBV infection (OBI) that are intermittently or not detectable even by highly sensitive individual donation (ID) NAT. Studies have reported HBV transfusion-transmission with blood components from donors with OBI that contained low amount of viruses (<200 virions). HBV transfusion-transmission seems to depend on a combination of several factors including the volume of plasma associated with the infected blood components transfused, the anti-HBV immune status of both recipient and donor, and possibly the viral fitness of the infecting HBV strain. Models based on clinical and experimental evidences estimate a residual transmission risk of 3-14% associated with OBI donations testing HBsAg and ID-NAT non-reactive. Anti-HBc testing has the potential to improve further blood safety but it may also compromise blood availability in settings with medium/high HBV prevalence. Pathogen reduction procedures might be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine - 24(2017), 3 vom: 03. Sept., Seite 189-195 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Candotti, D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.07.2018 Date Revised 19.07.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tracli.2017.06.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM273502832 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273502832 | ||
| 003 | DE-627 | ||
| 005 | 20231225001356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tracli.2017.06.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0911.xml |
| 035 | |a (DE-627)NLM273502832 | ||
| 035 | |a (NLM)28673499 | ||
| 035 | |a (PII)S1246-7820(17)30095-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Candotti, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Occult hepatitis B infection and transfusion-transmission risk |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2018 | ||
| 500 | |a Date Revised 19.07.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Advances in serology and viral nucleic acid testing (NAT) over the last decades significantly reduced the risk of transfusion-transmitted hepatitis B virus (HBV). The combination of HBsAg testing and NAT efficiently prevents the majority of HBV transmission. However, a specific residual risk remains associated with extremely low viral DNA levels in blood donors with occult HBV infection (OBI) that are intermittently or not detectable even by highly sensitive individual donation (ID) NAT. Studies have reported HBV transfusion-transmission with blood components from donors with OBI that contained low amount of viruses (<200 virions). HBV transfusion-transmission seems to depend on a combination of several factors including the volume of plasma associated with the infected blood components transfused, the anti-HBV immune status of both recipient and donor, and possibly the viral fitness of the infecting HBV strain. Models based on clinical and experimental evidences estimate a residual transmission risk of 3-14% associated with OBI donations testing HBsAg and ID-NAT non-reactive. Anti-HBc testing has the potential to improve further blood safety but it may also compromise blood availability in settings with medium/high HBV prevalence. Pathogen reduction procedures might be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Blood safety | |
| 650 | 4 | |a Détection du génome viral | |
| 650 | 4 | |a Hepatitis B virus | |
| 650 | 4 | |a Infection B occulte | |
| 650 | 4 | |a Nucleic acid testing | |
| 650 | 4 | |a Occult HBV infection | |
| 650 | 4 | |a Sécurité transfusionnelle | |
| 650 | 4 | |a Transfusion-transmission | |
| 650 | 4 | |a Transmission par transfusion | |
| 650 | 4 | |a Virus de l’hépatite B | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Hepatitis B Antibodies |2 NLM | |
| 650 | 7 | |a Hepatitis B Core Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 700 | 1 | |a Boizeau, L |e verfasserin |4 aut | |
| 700 | 1 | |a Laperche, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine |d 1994 |g 24(2017), 3 vom: 03. Sept., Seite 189-195 |w (DE-627)NLM074905449 |x 1953-8022 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2017 |g number:3 |g day:03 |g month:09 |g pages:189-195 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tracli.2017.06.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2017 |e 3 |b 03 |c 09 |h 189-195 | ||